ActoGeniX NV
This article was originally published in Start Up
Executive Summary
ActoGeniX is trying to tap into the industry's biologicals craze with a gut-centric delivery system that uses genetically modified bacteria to produce and deliver drugs. The company will develop its ActoBiotics for the treatment of severe gastrointestinal diseases, metabolic diseases, immune disorders, and allergies, where it feels that there is either an unmet need or its therapeutics can offer a significant advantage over existing products.
You may also be interested in...
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.
The Drug Delivery Road Gets Tougher
While making money in drug delivery has always been tougher than its boosters have promised, this year's been ugly in new and disturbing ways. The key lessons of Pfizer's abandonment of inhaled insulin and Impax's patent assault on Endo's Opana are that partners are less reliable; the products need to be medically superior to existing ones, not simply more convenient; and generic companies are making inroads into the main bastion of drug-delivery success -- spec pharma.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.